Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Summary
The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ICP-332 in Patients With Moderate to Severe Plaque Psoriasis
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
172
Start Date
2025-12-22
Completion Date
2027-05
Last Updated
2025-12-31
Healthy Volunteers
No
Conditions
Interventions
ICP-332 Tablets
ICP-332 will be administered as tablet for 12 weeks
ICP-332 Tablets
ICP-332 will be administered as tablet for 12 weeks
ICP-332 Tablets
ICP-332 will be administered as tablet for 12 weeks
ICP-332 Placebo Tablets
Placebo will be administered as tablet for 12 weeks
Locations (1)
Shanghai Dermatology Hospital
Shanghai, Shanghai Municipality, China